BMBF Clusters4Futures PROXIDRUGS

Innovative Therapies for Human Diseases: Targeted Degradation as New Mode of Action for Drugs (PROXIDRUGS)

The Future Cluster Initiative was started in 2019 with the goal of stimulating new value creation in Germany, thereby strengthening our position among the world's innovation leaders.

Germany's universities and research institutions are already excellently positioned in a wide variety of research fields. To transform fundamental insights—also in emerging fields of knowledge and research—into market-ready solutions more quickly, the BMBF decided that it requires brilliant minds, well-cooperating teams, and powerful concepts. The aim of the Clusters4future initative is to strengthen regional networks that bring together the diverse perspectives and competencies of a region.

PROXIDRUGS has been initated as a regional network of partners from academia and industry, covering the entire value chain from basic to translational research, and became a Cluster4Future funded by the BMBF since 2021. Academic participants are based at Goethe University Frankfurt, TU Darmstadt, University of Heidelberg, the MPI of Biophysics and the Fraunhofer Institute for Translational Medicine and Pharmacology, and they are closely working together with industry partners from the pharmaceutical sector. 

PROXIDRUGS Key Data

Coordinating Institution: Goethe University Frankfurt

Spokesperson: Prof. Dr. Ivan Đikić

Funding Period: 2021–2025

Projects Conducted at the MPI of Biophysics

Innovative Technologies for Proxidrugs (InnoTECH)

Investigator: Gerhard Hummer in cooperation with Christian Münch (Goethe University)
Term: 2021–2025

The goals of the project are the characterization of Proxidrugs target proteins and degradation mechanisms. Methods of quantitative proteomics, functional genomics and computational biology are adapted and further developed to PROXIDRUGS-specific questions. This will form the basis for future approaches to drug screening to test the degradation of target proteins in high throughput.
 

 

PROTACs Based on New E3 Ligands and Structured Linkers (NewPRO)

Investigator: Gerhard Hummer in cooperation with colleagues at Goethe University, TU Darmstadt, and Merck KGaA
Term: 2021–2025

PROTACs represent a new class of pharmacologically active compounds that have recently been investigated for the first time in clinical trials. NewPRO aims to improve the pharmacokinetic properties of PROTACs through the use of new E3 ligands and to significantly expand the possibilities of rational design by expanding the portfolio of established E3 ligands.

more on Cluster4Future initative Proxidrugs (official project website)

Web-View
Print Page
Open in new window
Estimated DIN-A4 page-width
Go to Editor View